Inactivation of p27kip1 promotes chemical hepatocarcinogenesis through enhancing inflammatory cytokine secretion and STAT3 signaling activation

Journal of Cellular Physiology

Volumn 228, Issue 10, 2013, Pages 1967-1976

  Guo, Jian ^a,c   Ma, Qingyong ^a   Zhou, Xiaojie ^b   Fan, Ping ^a   Shan, Tao ^a   Miao, Dengshun ^c  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b National Institutes for Food and Drug Control   (China)

^c Laboratory of Reproductive Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; INTERLEUKIN 6; MESSENGER RNA; PROTEIN P27; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; CDKN1B PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE;

ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; INFLAMMATION; INFLAMMATORY CELL; LIVER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPLEEN CELL; TUMOR CELL; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL GROWTH; CELL TRANSFORMATION; COCULTURE; GENETICS; KNOCKOUT MOUSE; LIVER TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

MUS;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COCULTURE TECHNIQUES; CYCLIN-DEPENDENT KINASE INHIBITOR P27; INFLAMMATION; INTERLEUKIN-6; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879539887     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24357     Document Type: Article

References (27)

1. Aravalli RN, Steer CJ, Cressman EN. 2008. Molecular mechanisms of hepatocellular carcinoma. Hepatology 48:2047-2063 [PubMed: 19003900].
2. Armengol C, Boix L, Bachs O, Sole M, Fuster J, Sala M, Llovet JM, Rodes J, Bruix J. 2003. p27 (Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma. J Hepatol 38:591-597 [PubMed: 12713869].
3. Balkwill F, Charles KA, Mantovani A. 2005. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211-217 [PubMed: 15766659].
4. Ben-Baruch A. 2006. Inflammation-associated immune suppression in cancer: The roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16:38-52 [PubMed: 16139507].
5. Boussiotis VA, Freeman GJ, Taylor PA, Berezovskaya A, Grass I, Blazar BR, Nadler LM. 2000. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med 6:290-297 [PubMed: 10700231].
6. Coussens LM, Werb Z. 2002. Inflammation cancer. Nature 420:860-867 [PubMed: 12490959].
7. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM. 1996. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85:733-744 [PubMed: 8646781].
8. Fiorentino M, Altimari A, D'Errico A, Cukor B, Barozzi C, Loda M, Grigioni WF. 2000. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res 6:3966-3972 [PubMed: 11051245].
9. Grivennikov SI, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M. 2009. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103-113 [PubMed: 19185845].
10. Grivennikov SI, Greten FR, Karin M. 2010. Immunity, inflammation, and cancer. Cell 140:883-899 [PubMed: 20303878].
11. He G, Karin M. 2011. NF-kappaB and STAT3-Key players in liver inflammation and cancer. Cell Res 21:159-168 [PubMed: 21187858].
12. Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, Travali S, Spandidos DA, Libra M. 2011. The tumor microenvironment in hepatocellular carcinoma. Int J Oncol 40:1733-1747 [PubMed: 22447316].
13. Lin WW, Karin M. 2007. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117:1175-1183 [PubMed: 17476347].
14. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. 2004. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNF-alpha to TRAIL-mediated tumor regression. Cancer Cell 6:297-305 [PubMed: 15380520].
15. McGlynn KA. London WT 2011. The global epidemiology of hepatocellular carcinoma: Present and future. Clin Liver Dis 15:223-243, vii-x [PubMed: 21689610].
16. Merle P, Trepo C, 2009. Molecular mechanisms underlying hepatocellular carcinoma. Viruses 1:852-872 [PubMed: 21994573].
17. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. 2007. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317:121-124 [PubMed: 17615358].
18. Pang XH, Zhang JP, Zhang YJ, Yan J, Pei XQ, Zhang YQ, Li JQ, Zheng L, Chen MS. 2011. Preoperative levels of serum interleukin-6 in patients with hepatocellular carcinoma. Hepatogastroenterology 58:1687-1693 [PubMed: 21940335].
19. Park EJ, Lee JH. Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. 2009. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140:197-208 [PubMed: 20141834].
20. Peroukides S, Bravou V, Alexopoulos A, Varakis J, Kalofonos H, Papadaki H. 2010. Survivin overexpression in HCC and liver cirrhosis differentially correlates with p-STAT3 and E-cadherin. Histol Histopathol 25:299-307 [PubMed: 20054802].
21. Prieto J. 2008. Inflammation HCC and sex: IL-6 in the centre of the triangle. J Hepatol 48:380-381 [PubMed: 18093689].
22. Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G, Karin M. 2008. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14:156-165 [PubMed: 18691550].
23. Sherr CJ, Roberts JM. 1999. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512 [PubMed: 10385618].
24. Sun D, Ren H, Oertel M, Sellers RS, Zhu L. 2007. Loss of p27Kip1 enhances tumor progression in chronic hepatocyte injury-induced liver tumorigenesis with widely ranging effects on Cdk2 or Cdc2 activation. Carcinogenesis 28:1859-1866 [PubMed: 17434927].
25. Sun D, Ren H, Oertel M, Sellers RS, Shafritz DA, Zhu L. 2008. Inactivation of p27Kip1 promotes chemical mouse liver tumorigenesis in the resistant strain C57BL/6J. Mol Carcinog 47:47-55 [PubMed: 17620307].
26. Tretiakova MS, Shabani-Rad MT, Guggisberg K, Hart J, Anders RA, Gao ZH. 2010. Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis. Histopathology 56:683-693 [PubMed: 20546333].
27. Wu WY, Li J, Wu ZS, Zhang CL, Meng XL. 2011. STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer 11:506 [PubMed: 22136659].